Inspiremd Inc (NSPR)

$2.39 -0.02 (-0.83%)
Market Cap 99.71M
Revenue (ttm) 7.01M
Net Income (ttm) -32.01M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -456.63%
Debt to Equity Ratio 0.00
Volume 57,400
Avg Vol 114,602
Day's Range N/A - N/A
Shares Out 41.72M
Stochastic %K 25%
Beta 0.60
Analysts Strong Sell
Price Target $4.50

Company Profile

InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery and other vascular diseases in Europe, Latin America, the Middle East, and the Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard neuroprotection system for transcarotid access and neuro protection, as w...

Industry: Medical Devices
Sector: Healthcare
Phone: 888 776 6804
Address:
6303 Waterford District Drive, Suite 215, Miami, United States
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 4 at 10:57 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $NSPR Current Share Price: $2.39 Contracts: $NSPR May 15, 2026 $2 Calls Scale in: $1.22- $1.49 Scale out: $1.90-$2.44 Can Easily Capture: 60% ROI Blended DTE: 224 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Ronnie5isAlive
Ronnie5isAlive Oct. 3 at 2:49 PM
$NSPR “paytience” worked out great.
1 · Reply
HOBOWITHASHOTGUN
HOBOWITHASHOTGUN Oct. 3 at 2:11 PM
$NSPR Wow - the shorts are starting in - a sign of incoming change...
3 · Reply
Faysi
Faysi Oct. 2 at 9:55 PM
$NSPR Solomon is a fraud 👀
0 · Reply
JBinLB
JBinLB Oct. 2 at 7:02 PM
$NSPR this is a stagnant turd sandwich change my mind
0 · Reply
Faysi
Faysi Oct. 2 at 6:45 PM
$NSPR Bankruptcy soon 🤫😜
1 · Reply
Luka2024
Luka2024 Oct. 2 at 5:46 PM
$NSPR
0 · Reply
Ronnie5isAlive
Ronnie5isAlive Oct. 2 at 12:41 PM
$NSPR looking forward to owning this stock through another bout of seasonal depression. Bah humbug.
2 · Reply
Thespectator
Thespectator Oct. 1 at 1:28 AM
$NSPR dead money for years when markets go boom boom, must be maddening 😆
1 · Reply
Threeways
Threeways Sep. 30 at 8:08 PM
$NSPR goes from 930,000 shares traded to 4,500 shares 😅. Guess we can chalk today up as a slow day
0 · Reply
Latest News on NSPR
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 25, 2025, 4:05 PM EDT - 9 days ago

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

InspireMD Announces the Appointment of Dan Dearen to its Board of Directors

Sep 17, 2025, 8:00 AM EDT - 17 days ago

InspireMD Announces the Appointment of Dan Dearen to its Board of Directors

InspireMD to Present at Upcoming H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 9:00 AM EDT - 5 weeks ago

InspireMD to Present at Upcoming H.C. Wainwright 27th Annual Global Investment Conference

InspireMD, Inc. (NSPR) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 12:30 PM EDT - 2 months ago

InspireMD, Inc. (NSPR) Q2 2025 Earnings Call Transcript

InspireMD Reports Second Quarter 2025 Financial Results

Aug 5, 2025, 8:00 AM EDT - 2 months ago

InspireMD Reports Second Quarter 2025 Financial Results

InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors

Jul 31, 2025, 8:31 AM EDT - 2 months ago

InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors

InspireMD Announces Combined Financings of $58 Million

Jul 31, 2025, 8:30 AM EDT - 2 months ago

InspireMD Announces Combined Financings of $58 Million

InspireMD to Announce Second Quarter 2025 Financial Results

Jul 22, 2025, 7:00 AM EDT - 2 months ago

InspireMD to Announce Second Quarter 2025 Financial Results

InspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid Stent System for the Prevention of Stroke

Jul 9, 2025, 7:00 AM EDT - 3 months ago

InspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid Stent System for the Prevention of Stroke

InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke

Jun 24, 2025, 4:05 PM EDT - 3 months ago

InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke

InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke

Jun 13, 2025, 9:00 AM EDT - 4 months ago

InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke

InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer

Jun 3, 2025, 4:05 PM EDT - 4 months ago

InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer

InspireMD, Inc. (NSPR) Q1 2025 Earnings Call Transcript

May 9, 2025, 12:07 PM EDT - 5 months ago

InspireMD, Inc. (NSPR) Q1 2025 Earnings Call Transcript

InspireMD Reports First Quarter 2025 Financial Results

May 9, 2025, 7:00 AM EDT - 5 months ago

InspireMD Reports First Quarter 2025 Financial Results

InspireMD to Present at Upcoming Bank of America 2025 Healthcare Conference

Apr 30, 2025, 9:00 AM EDT - 5 months ago

InspireMD to Present at Upcoming Bank of America 2025 Healthcare Conference

InspireMD to Announce First Quarter 2025 Financial Results

Apr 25, 2025, 9:00 AM EDT - 5 months ago

InspireMD to Announce First Quarter 2025 Financial Results

InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference

Mar 26, 2025, 9:00 AM EDT - 6 months ago

InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference

InspireMD, Inc. (NSPR) Q4 2024 Earnings Call Transcript

Mar 12, 2025, 1:53 PM EDT - 7 months ago

InspireMD, Inc. (NSPR) Q4 2024 Earnings Call Transcript

InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 12, 2025, 7:00 AM EDT - 7 months ago

InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results

InspireMD to Announce Fourth Quarter and Full Year 2024 Financial Results

Feb 26, 2025, 8:00 AM EST - 7 months ago

InspireMD to Announce Fourth Quarter and Full Year 2024 Financial Results

InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime™ 80 cm Carotid Stent System for Use in TCAR procedures

Feb 13, 2025, 7:00 AM EST - 8 months ago

InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime™ 80 cm Carotid Stent System for Use in TCAR procedures

InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)

Dec 9, 2024, 7:00 AM EST - 10 months ago

InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)

InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors

Nov 25, 2024, 4:05 PM EST - 11 months ago

InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors

InspireMD, Inc. (NSPR) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 10:20 AM EST - 11 months ago

InspireMD, Inc. (NSPR) Q3 2024 Earnings Call Transcript

InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System

Oct 15, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System

InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System

Oct 7, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System

InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System

Sep 16, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System

InspireMD, Inc. (NSPR) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 8:58 AM EDT - 1 year ago

InspireMD, Inc. (NSPR) Q2 2024 Earnings Call Transcript

InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 6, 2024, 8:09 AM EDT - 1 year ago

InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update

InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment

Aug 5, 2024, 7:00 AM EDT - 1 year ago

InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment

InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th

Jul 30, 2024, 7:00 AM EDT - 1 year ago

InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th

InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024

May 28, 2024, 8:53 AM EDT - 1 year ago

InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024

InspireMD Inc. (NSPR) Q1 2024 Earnings Call Transcript

May 14, 2024, 10:50 AM EDT - 1 year ago

InspireMD Inc. (NSPR) Q1 2024 Earnings Call Transcript

InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update

May 14, 2024, 7:00 AM EDT - 1 year ago

InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update

InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th

May 7, 2024, 7:00 AM EDT - 1 year ago

InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th

InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference

Apr 3, 2024, 8:59 AM EDT - 1 year ago

InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference

InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024

Mar 26, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024

InspireMD Inc. (NSPR) Q4 2023 Earnings Call Transcript

Mar 6, 2024, 11:30 AM EST - 1 year ago

InspireMD Inc. (NSPR) Q4 2023 Earnings Call Transcript

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Mar 6, 2024, 7:00 AM EST - 1 year ago

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th

Feb 28, 2024, 7:00 AM EST - 1 year ago

InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th

InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System

Feb 12, 2024, 7:00 AM EST - 1 year ago

InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System

InspireMD Receives CE Mark Recertification Under EU's New Medical Device Regulation (MDR) Regulatory Framework

Jan 31, 2024, 7:00 AM EST - 1 year ago

InspireMD Receives CE Mark Recertification Under EU's New Medical Device Regulation (MDR) Regulatory Framework

InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America

Jan 3, 2024, 7:00 AM EST - 1 year ago

InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America

InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System

Dec 20, 2023, 7:00 AM EST - 1 year ago

InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System

InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions

Nov 27, 2023, 7:00 AM EST - 2 years ago

InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions

InspireMD Inc. (NSPR) Q3 2023 Earnings Call Transcript

Nov 6, 2023, 11:09 AM EST - 2 years ago

InspireMD Inc. (NSPR) Q3 2023 Earnings Call Transcript

InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 6, 2023, 7:00 AM EST - 2 years ago

InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update

InspireMD to Participate in Upcoming November Investor Conferences

Nov 2, 2023, 8:00 AM EDT - 2 years ago

InspireMD to Participate in Upcoming November Investor Conferences

InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23

Nov 1, 2023, 2:19 PM EDT - 2 years ago

InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23

InspireMD to Report Third Quarter 2023 Financial Results and Provide Corporate Business Update on Monday, November 6th

Oct 30, 2023, 9:21 AM EDT - 2 years ago

InspireMD to Report Third Quarter 2023 Financial Results and Provide Corporate Business Update on Monday, November 6th

LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 4 at 10:57 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $NSPR Current Share Price: $2.39 Contracts: $NSPR May 15, 2026 $2 Calls Scale in: $1.22- $1.49 Scale out: $1.90-$2.44 Can Easily Capture: 60% ROI Blended DTE: 224 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Ronnie5isAlive
Ronnie5isAlive Oct. 3 at 2:49 PM
$NSPR “paytience” worked out great.
1 · Reply
HOBOWITHASHOTGUN
HOBOWITHASHOTGUN Oct. 3 at 2:11 PM
$NSPR Wow - the shorts are starting in - a sign of incoming change...
3 · Reply
Faysi
Faysi Oct. 2 at 9:55 PM
$NSPR Solomon is a fraud 👀
0 · Reply
JBinLB
JBinLB Oct. 2 at 7:02 PM
$NSPR this is a stagnant turd sandwich change my mind
0 · Reply
Faysi
Faysi Oct. 2 at 6:45 PM
$NSPR Bankruptcy soon 🤫😜
1 · Reply
Luka2024
Luka2024 Oct. 2 at 5:46 PM
$NSPR
0 · Reply
Ronnie5isAlive
Ronnie5isAlive Oct. 2 at 12:41 PM
$NSPR looking forward to owning this stock through another bout of seasonal depression. Bah humbug.
2 · Reply
Thespectator
Thespectator Oct. 1 at 1:28 AM
$NSPR dead money for years when markets go boom boom, must be maddening 😆
1 · Reply
Threeways
Threeways Sep. 30 at 8:08 PM
$NSPR goes from 930,000 shares traded to 4,500 shares 😅. Guess we can chalk today up as a slow day
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Sep. 30 at 4:51 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $NSPR Current Share Price: $2.38 Contracts: $NSPR May 15, 2026 $2 Calls Scale in: $0.42- $0.51 Scale out: $0.65-$0.84 Can Easily Capture: 60% ROI Blended DTE: 228 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
LoyalShark
LoyalShark Sep. 30 at 11:40 AM
$NSPR Slosman has been a DISASTER in creating value for the shareholder. His reflection is in the $2.42 / share mirror. Since Slosman --- the stock is down 98%. Slosman just does not have what it takes to create value in the market for shareholders. He struggles at everything market. Just a complete avoidable shame. PRAYING for a buy out.
0 · Reply
Ronnie5isAlive
Ronnie5isAlive Sep. 30 at 2:02 AM
$NSPR hello?
2 · Reply
LoyalShark
LoyalShark Sep. 29 at 3:25 PM
$NSPR At what point does the company let us know how the sales are going ??? Must not be good to not be hearing anything.
1 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Sep. 29 at 2:13 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $NSPR Current Share Price: $2.39 Contracts: $NSPR May 15, 2026 $2 Calls Scale in: $1.24- $1.52 Scale out: $1.93-$2.48 Can Easily Capture: 60% ROI Blended DTE: 229 Days | Join Elites here: https://liquidtheta.com
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Sep. 27 at 11:17 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $NSPR Current Share Price: $2.41 Contracts: $NSPR February 20, 2026 $2 Calls Scale in: $0.32- $0.39 Scale out: $0.49-$0.63 Can Easily Capture: 60% ROI Blended DTE: 147 Days | Join Elites here: https://liquidtheta.com
0 · Reply
MasterOfMyDomains
MasterOfMyDomains Sep. 26 at 7:32 PM
$NSPR
0 · Reply
_stonedBAPEtheory_
_stonedBAPEtheory_ Sep. 26 at 7:30 PM
$NSPR 6 month chart is wild
0 · Reply
HOBOWITHASHOTGUN
HOBOWITHASHOTGUN Sep. 26 at 7:18 PM
$NSPR Everyone be quiet and let the 'Investorbots' do their work... If you need excitement check out $APDN or bask in the collapse of $INDP
0 · Reply
TimRegan_WTR
TimRegan_WTR Sep. 26 at 6:17 PM
$NSPR
0 · Reply
research_WTR
research_WTR Sep. 26 at 6:15 PM
Read Robert Sassoon's recap from his recent Healthcare Happenings podcast with Marvin Slosman, CEO of InspireMD (NASDAQ: NSPR). Those interested can listen to this podcast on Apple Podcasts, Spotify, or on our website. Links are accessible in our full report! https://www.watertowerresearch.com/doc?docID=IR_Healt_09252025 $NSPR #InspireMD #Healthcare #Podcast #SmallCap #Stocks #Investing #CGuard #Stent #WTRInsights
0 · Reply
rcarigl23
rcarigl23 Sep. 26 at 6:01 PM
$NSPR extremely boring……🙈🙉🙊
0 · Reply